George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Spot on - it's the reason I'm invested, would love an update on CiRT, but me thinks we may have to wait until after Xmas... I really don't think the management are getting credit for what they've achieved in such a short timeline
Well - Dug .. you can now buy back if you wish at profit (wish I sold some of my golden tickets now :0)
Chill -Nothing posted on these boards affect your investment, only your faith in humanity!!!
Uk is obviously a market that OBD would like to have , and the BUPA Deal is by far the biggest OBD have achieved so far .. but it has been stated many many times in presentations etc that they are looking to penetrate the US Market , they are mostly based in the US and me VP on sales is based in the US .. UK IS Small fry .. Whilst the addressable market is only 5 times bigger , the Private Medical sector is 100's of time bigger dwarfing the NHS at least tenfold .. BUPA seal covers over 2 million people for CIrt and that can be done with one signature .. same can be done in the US .. forget NHS it's not worth the effort -(as many a CEO will tell you)
I fully agree - not sure why PSE NHS taking up so much keystrokes ! TBH it's not even up for debate - OBD have made thier strategy very clear in the presentations ..
Agree - by the time this trail completes OBD will already completed much more on its own .. still would be good to be a part of it .. as long as OBD are not expended to Fund it
Hi Dug
At least your being transparent, however I think you are showing the classic errors of a PI - you first starting posing on OBD late Sept after a massive rise and have not had any acceptance of anything even possibly negative IMO we've had two fantastic RNS since you bought it - Now .. worried of paper losses make irrational decisions based on fear and greed .. Buy High - Sell low .. whether that is right or wrong remains to be seen However your 360 based on nothing shows a lot ..IMO , now it's all negative angle .. I'm alway up for a debate as it's alway better to look deep at the negatives .. However you appear unsure of your convictions and now feel the need to justify your losses .. all been there. Good Luck All
Morning
Some good posts , many thanks. For me - I think there is way too much focus on PSE, whilst exciting , In this finacial year its more likely to contribute very little revenue wise.. I'm very focused on Cirt - The company is not cash rich and the success of Cirt this year will dictate the rise or fall of our investment, its of primary importance for a loss making company.. To that end I feel that we are starting to see the OBD strategy unfold (which will be similar for PSE) If you look at the latest presentation OBD are now quoting realy life case studies.. therefore we know that they are getting real life data on the sucess of Cirt (that they can use) This will build up into the 100's very soon ..and form all the data for things like FDA/NICE applications.. There im eagerly awaiting the next update, If CIRt is performing with only modest we are off the the races .. If not the SP will fall as further funding would needed.. TBH that my only concern .. Not funding itself (mo problen getting funding when you are bringing in the bacon), but not so easy when you have no meaningful revenues.. SP will thrive or die on Cirt IMO
Updated end of last week - Nothing really new, just beefed up the tech info a bit and started adding in case studies etc.
https://d1io3yog0oux5.cloudfront.net/_0e5e76377c53bf35676d02844d5ec865/oxfordbiodynamics/db/2553/24445/pdf/Oxford+BioDynamics+Company+Presentation+Nov+08+2023.pdf
My logic is that whist HNS trails etc are good for the long term , they are so slow and nornally expensive for the participants, I would welcome the news with open arms.. and would be great, but the private sector moves quicker , much much quicker and OBD have made thier strategy quite clear.. I dont expect fireworks on PSE within weeks of release, that would be foolish but the seeds have been sown very impressively - Medicare code in 3 months deserves a round of applause as does the BUPA deal
All the Best, I'm focused on pick up of CIrt .. PSE will get deals .. maybe not within the timeframe of LSE BB members but they will - We know they are in ear shot of BUPA (much easier than NHS tp procress common sence and already got a Medicare code in the US, but standard practice of care will take time.. I still dont quite understand how youve deduced they are not involved .. would be great "additional news" but either way not that bothered Cheers
Good post 404x - The Facts havent changed at all , very odd way to investIMO, but each to his own we all have to make our choices and been wrong more times than I'm right TBH. Best of Luck
I dont think anyone on here knows what discussions are taking place, However why sweat it on every piece of assumed news ? This is not a one tricky pony - and vaultations of BIO have been hammered, plus weve most likely reached a peak in interest rates.. buy low sell high .. last 3 rns's are well worth the SP - CIRT/BUPA on its own
Hi Dug, Your call , but seems a bit of a knee Jerk reaction.. The company has made it clear for some time that it was not focusing on thre NHS /NICE at this point in time, they belive the money is in the US private sector.. for me PSE is not the revenue driver..CIRT is what will drive the perfonace of the company this year..
BTW Website traffic for 94percent was up 416% in October over September - number need to be taken with a large pinch of salt as the site didnt even register on google at first - Good Luck to you
I agree Dug - Not to be blinkered though, alway worth looking at the negatives, However rubbish about listing on the US aetc and useless Management are just rumblings from buying in too high .. Revenue wise Im not exptecting firework in the H2 numbers - OBD have already stated they block apply for reinbursment and do not reconise revunes until its paid, which mean the revs for H2 31sept .. will stop end of June / Maybe July. So we can pretty much works those out ourselves already. For me its the monthly run rate on CIRT Thats the Key, Its the product that has now had time to start to payback and last snapshot was very exciting . PSE can wait, It will take time to penetrate .. Loads of news to come , Happy to sit here an read the rubbish on here for now :)
To go from concept to launch and medicare code in a tad over 6 months,- is an unbelivable achievement, totally unheard of.. Never seen that in 30 years of investing.and after securing BUPA and 40%+ of the UK private insuremnt market for Cirt, Now I'm bored and managemet are usless, selling out at a loss.. bonkers .. If these board are a snapshot of the investing world we are all doomed to going back to the caves... Gambling is not investing
Agree - lots of ST buys chasing spikes ,leads to drip sells.. AIM is full of gamblers with the attention span of a goldfish.. Way too much going on to even risk not keep this as a core holding.. All good.. I dont think NHS is the priority for PSE myself - As per Cirt , penetrate the private sector first US with UK Private / BUPA in tandem..
Steves Bio, lets hope he can better his performance at OBD
I am a scientist by training who dove into business development in 2006 and hasn't looked back. Seventeen year track record in the CRO and Diagnostic space with increasing revenues and responsibilities. Grew the West Region with Caprion/Caprion-HistoGeneX/CellCarta 36x in 4 years. My skills are in Pharmaceutical client discovery, development, and management, presentations, contract development and negotiation, companion diagnostics co-development, and marketing.
Morning = Yes looks a good strong appointment.. Punching by getting him, looks a great addition.. OBD is really showing so determination and momentum at the moment .
Krull - More like loss takers buying on a spike, then selling out after a day or less.. still go the other 9% floating around somewhere in cyberspace... GLA
Cellcarta will make a great partner - over 1000 employess and leader in Biomarker Services
As a global Contract Research Organization Laboratory (CRO) to the biopharmaceutical industry, CellCarta provides access to a broad offering of biomarker platforms and services. We partner with you to address the most complex scientific testing needs, delivering customized biomarker testing solutions to further the limitless potential of precision medicine.